Dectin-1/IL-15 Pathway Affords Protection against Extrapulmonary Aspergillus fumigatus Infection by Regulating Natural Killer Cell Survival

被引:0
|
作者
Yoshikawa, Fabio S. Y. [1 ]
Wakatsuki, Maki [1 ]
Yoshida, Kosuke [1 ]
Yabe, Rikio [1 ]
Torigoe, Shota [2 ]
Yamasaki, Sho [1 ,2 ,3 ,4 ]
Barber, Glen N. [5 ]
Saijo, Shinobu [1 ]
机构
[1] Chiba Univ, Med Mycol Res Ctr, Div Mol Immunol, Chiba, Japan
[2] Osaka Univ, Microbial Dis Res Inst, Dept Mol Immunol, Suita, Osaka, Japan
[3] Osaka Univ, Immunol Frontier Res Ctr, Lab Mol Immunol, Suita, Osaka, Japan
[4] Kyushu Univ, Med Inst Bioregulat, Div Mol Design, Fukuoka, Japan
[5] Univ Miami, Miller Sch Med, Dept Cell Biol, Miami, FL USA
关键词
Aspergillus fumigatus; Dectin-1; IL-15; NK cells; BETA-GLUCAN RECEPTOR; INVASIVE ASPERGILLOSIS; NEUTROPHILS; DEFENSE; SUSCEPTIBILITY; RESPONSES; INFLAMMATION; MECHANISMS; EXPRESSION; MORTALITY;
D O I
10.1159/000527188
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Aspergillus fumigatus is a ubiquitous, yet potentially pathogenic, mold. The immune system employs innate receptors, such as dectin-1, to recognize fungal pathogens, but the immunological networks that afford protection are poorly explored. Here, we investigated the role of dectin-1 in anti-A. fumigatus response in an experimental model of acute invasive aspergillosis. Mice lacking dectin-1 presented enhanced signs of inflammation, with increased production of inflammatory cytokines and neutrophil infiltration, quickly succumbing to the infection. Curiously, resistance did not require T/B lymphocytes or IL-17. Instead, the main effector function of dectin-1 was the preservation of the NK cell population in the kidneys by the provision of the cytokine IL-15. While the depletion of NK cells impaired host defense in wild-type mice, IL-15 administration restored antifungal responses in dectin-1- deficient mice. Our results uncover a new effector mechanism for dectin-1 in anti-Aspergillus defense, adding an alternative approach to understand the pathophysiology of this infection. (c) 2023 The Author( s). Published by S. Karger AG, Basel
引用
收藏
页码:397 / 411
页数:15
相关论文
共 19 条
  • [11] Monocytes enhance cell proliferation and LMP1 expression of nasal natural killer/T-cell lymphoma cells by cell contact-dependent interaction through membrane-bound IL-15
    Ishii, Hideyuki
    Takahara, Miki
    Nagato, Toshihiro
    Kis, Lorand L.
    Nagy, Noemi
    Kishibe, Kan
    Harabuchi, Yasuaki
    Klein, Eva
    INTERNATIONAL JOURNAL OF CANCER, 2012, 130 (01) : 48 - 58
  • [12] A phase 1 trial of cytokine-induced memory-like (CIML) natural killer (NK) cell therapy with IL-15 superagonist in advanced head and neck cancer: Part 1 results.
    Hanna, Glenn J.
    Coleman, Kimberly
    Birch, Grace
    Redd, Robert A.
    Alonso, Alejandro
    Bednarz, Samantha
    Daley, Heather
    Rodriguez, Diego E. Hernandez
    Shaw, Kit L.
    Haddad, Robert I.
    Uppaluri, Ravindra
    Ritz, Jerome
    Nikiforow, Sarah
    Soiffer, Robert J.
    Romee, Rizwan
    CANCER RESEARCH, 2022, 82 (12)
  • [13] TLR3/TRIF pathway confers protection against herpes simplex encephalitis through NK cell activation mediated by a loop of type I IFN and IL-15 from epithelial and dendritic cells
    Uyangaa, Erdenebileg
    Choi, Jin Young
    Park, Seong Ok
    Byeon, Hee Won
    Cho, Hye Won
    Kim, Koanhoi
    Eo, Seong Kug
    IMMUNOLOGY, 2023, 170 (01) : 83 - 104
  • [14] Case report: PD-L1-targeted high-affinity natural killer cells and IL-15 superagonist N-803-based therapy extend overall survival of advanced metastatic pancreatic cancer patients
    Seery, Tara
    Sender, Lennie
    Jafari, Omid
    Jones, Frank
    Spilman, Patricia
    Reddy, Sandeep B.
    Soon-Shiong, Patrick
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [15] Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice
    Chu, Yaya
    Nayyar, Gaurav
    Jiang, Susiyan
    Rosenblum, Jeremy M.
    Soon-Shiong, Patrick
    Safrit, Jeffrey T.
    Lee, Dean A.
    Cairo, Mitchell S.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 8 (07)
  • [16] Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: Comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression
    Decot, Veronique
    Voillard, Laure
    Latger-Cannard, Veronique
    Aissi-Rothe, Lamia
    Perrier, Pascale
    Stoltz, Jean Francois
    Bensoussan, Daniele
    EXPERIMENTAL HEMATOLOGY, 2010, 38 (05) : 351 - 362
  • [17] Human immunodeficiency virus (HIV) type-1 GP120-specific cell-mediated cytotoxicity (CMC) and natural killer (NK) activity in HIV-infected (HIV+) subjects. Enhancement with interleukin-2(IL-2), IL-12, and IL-15
    Lin, SJ
    Roberts, RL
    Ank, BJ
    Nguyen, QH
    Thomas, EK
    Stiehm, ER
    CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1997, 82 (02): : 163 - 173
  • [18] Results from a First-in-Human Study with Bnz-1: A Novel Peptide Inhibitor of IL-2, IL9 and IL-15 for the Treatment of T-Cell Malignancies That Safely and Selectively Decreases Regulatory T-Cells, Natural Killer Cells, and CD8+ Central Memory T-Cells
    Frohna, Paul
    Tagaya, Yutaka
    Ratnayake, Anoshie
    Doerr, Nick
    Basheer, Asjad
    Al-Mawsawi, Laith
    Kim, Woo Jae
    Zapata, Juan
    Wu, Xisorong
    Azimi, Nazli
    BLOOD, 2017, 130
  • [19] A phase 1 trial of umbilical cord blood-derived tumor-reactive PD-L1+natural killer cells engineered to express soluble IL-15 (TRACK-NK) in patients with non-small-cell lung cancer (NSCLC) refractory to PD-1/PD-L1 inhibitors
    Villalona-Calero, Miguel Angel
    Forman, Stephen J.
    Palmer, Joycelynne
    Synold, Timothy W.
    Tian, Lei
    Lu, Ting
    Egelston, Colt A.
    Massarelli, Erminia
    Salgia, Ravi
    Kim, Teresa
    Meisen, Whans
    Zhang, Jianying
    Waddington, Thomas
    Boas, F. Edward
    Budde, Lihua Elizabeth
    Butt, Omer
    Vezan, Remus N.
    Caligiuri, Michael A.
    Yu, Jianhua
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)